Summary
Boston Scientific Corporation (BSX) reported strong financial performance for the third quarter and first nine months of 2024, demonstrating significant year-over-year growth in net sales. For the third quarter, net sales increased by 19.4% to $4.209 billion, driven by robust operational growth across its segments, particularly in Cardiology and MedSurg. Net income attributable to common stockholders was $469 million, or $0.32 per diluted share. For the first nine months, net sales grew 15.9% to $12.186 billion, with net income attributable to common stockholders at $1.288 billion, or $0.87 per diluted share. The company highlighted strong commercial execution and the successful adoption of new products, notably the Farapulse™ Pulsed Field Ablation System, as key drivers of this performance. Acquisitions, including Silk Road Medical, also contributed to the growth. Financially, the company maintained a solid balance sheet with $2.502 billion in unrestricted cash and cash equivalents as of September 30, 2024. Management expressed confidence in the company's liquidity and ability to fund operations, investments, and potential acquisitions. The company is progressing towards the expected closing of the Axonics acquisition in the fourth quarter of 2024, subject to regulatory approvals.
Financial Highlights
50 data points| Revenue | $4.21B |
| Cost of Revenue | $1.31B |
| Gross Profit | $2.90B |
| SG&A Expenses | $1.56B |
| Operating Expenses | $2.16B |
| Operating Income | $733.00M |
| Interest Expense | $79.00M |
| Net Income | $468.00M |
| EPS (Basic) | $0.32 |
| EPS (Diluted) | $0.32 |
| Shares Outstanding (Basic) | 1.47B |
| Shares Outstanding (Diluted) | 1.49B |
Key Highlights
- 1Net sales for Q3 2024 grew 19.4% year-over-year to $4.209 billion, with strong operational net sales growth of 19.5%.
- 2Net sales for the first nine months of 2024 increased 15.9% to $12.186 billion.
- 3Net income attributable to Boston Scientific common stockholders was $469 million ($0.32/share) for Q3 2024 and $1.288 billion ($0.87/share) for the first nine months of 2024.
- 4The company completed the acquisition of Silk Road Medical in Q3 2024, which contributed to revenue growth.
- 5The acquisition of Axonics is expected to close in Q4 2024, pending regulatory approval.
- 6Unrestricted cash and cash equivalents stood at $2.502 billion as of September 30, 2024, indicating strong liquidity.
- 7The Farapulse™ Pulsed Field Ablation System is experiencing rapid adoption and contributing significantly to growth, particularly in the Cardiology segment.